Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis
Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis. A Phase 2b, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Dose Ranging
Study of Oral PF-06651600 and PF-06700841 as Induction and Chronic Therapy in Subjects With Moderate to Severe Ulcerative Colitis.
Category & Conditions: Immune System Diseases and Conditions
Medicine: ritlecitinib (PF-06651600) / brepocitinib (PF-06700841)
ClinicalTrials.gov Identifier (NCT): NCT02958865
Protocol ID: B7981005
PrintDownloadOpen Plain Language Summary Result: Click here